Societal CDMO, Inc. (SCTL)

NASDAQ: SCTL · IEX Real-Time Price · USD
0.770
-0.020 (-2.54%)
May 24, 2022 4:30 PM EDT - Market closed
Market Cap43.38M
Revenue (ttm)79.75M
Net Income (ttm)-8.87M
Shares Out56.35M
EPS (ttm)-0.26
PE Ration/a
Forward PE18.25
Dividendn/a
Ex-Dividend Daten/a
Volume46,559
Open0.795
Previous Close0.790
Day's Range0.773 - 0.812
52-Week Range0.773 - 2.670
Betan/a
AnalystsBuy
Price Target5.10 (+562.4%)
Earnings DateMay 11, 2022

About SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logis...

IndustryDrug Manufacturers-Specialty & Generic
IPO DateMar 7, 2014
Employees185
Stock ExchangeNASDAQ
Ticker SymbolSCTL
Full Company Profile

Financial Performance

In 2021, Societal CDMO's revenue was $75.36 million, an increase of 13.33% compared to the previous year's $66.50 million. Losses were -$11.37 million, -58.66% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SCTL stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 562.42% from the latest price.

Price Target
$5.1
(562.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Societal to Participate in Upcoming Investor Conferences

SAN DIEGO and GAINESVILLE, Ga., May 19, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated t...

5 days ago - GlobeNewsWire

Societal CDMO Reports First Quarter 2022 Financial Results

Recorded Q1 Revenue of $21 Million; A 26% Increase Compared to Prior Year Period

1 week ago - GlobeNewsWire

Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe

Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023 Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023

2 weeks ago - GlobeNewsWire

Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022

Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. Eastern

2 weeks ago - GlobeNewsWire

Societal CDMO Secures Manufacturing and Packaging Task Order Award from National Cancer Institute (NCI)

SAN DIEGO and GAINESVILLE, Ga., April 27, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving co...

3 weeks ago - GlobeNewsWire

Down 25.9% in 4 Weeks, Here's Why Societal CDMO (SCTL) Looks Ripe for a Turnaround

Societal CDMO (SCTL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimat...

4 weeks ago - Zacks Investment Research

Societal CDMO Reports Inducement Grants for New Staff

SAN DIEGO and GAINESVILLE, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving co...

1 month ago - GlobeNewsWire

Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society

2 months ago - GlobeNewsWire

Recro Reports Fourth Quarter and Year End 2021 Financial Results

Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million

2 months ago - GlobeNewsWire

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern

3 months ago - GlobeNewsWire

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of To...

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex for...

3 months ago - GlobeNewsWire

Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego

Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations

4 months ago - GlobeNewsWire

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex form...

4 months ago - GlobeNewsWire

Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Recro Reports Third Quarter 2021 Financial Results

Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities

6 months ago - GlobeNewsWire

Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka

Agreement Establishes Recro as Commercial Supplier for Otsuka

6 months ago - GlobeNewsWire

Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic

Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).  The...

7 months ago - Benzinga

Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Sp...

New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturi...

7 months ago - GlobeNewsWire

Recro Reports Inducement Grants For New Staff

Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego

7 months ago - GlobeNewsWire

Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

7 months ago - Zacks Investment Research

Recro Signs Renewable Energy Agreement With Georgia Power

Investment in Renewable Energy Credits Represents Key Component of Company's Ongoing Environmental Sustainability Program Investment in Renewable Energy Credits Represents Key Component of Company's Ong...

8 months ago - GlobeNewsWire

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 months ago - Zacks Investment Research

Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth

9 months ago - GlobeNewsWire

Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO

Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms

9 months ago - GlobeNewsWire

Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO

EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufa...

9 months ago - GlobeNewsWire